Bioventus Inc. (BVS) Tops Q4 EPS by 4c ; Offers Guidance

Bioventus Inc. (NASDAQ: BVS) reported Q4 EPS of $0.24, $0.04 better than the analyst estimate of $0.20. Revenue for the quarter came in at $157.9 million versus the consensus estimate of $156.08 million.

GUIDANCE:

Bioventus Inc. sees FY2026 EPS of $0.73-$0.77, versus the consensus of $0.77. Bioventus Inc. sees FY2026 revenue of $600-610 million, versus the consensus of $604.2 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• BetterLife Pharma files final prospectus for $100M public offering
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue